Eledon Pharmaceuticals (ELDN) Total Non-Current Liabilities (2015 - 2026)

Eledon Pharmaceuticals (ELDN) has 12 years of Total Non-Current Liabilities data on file, last reported at $15.8 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 32.78% year-over-year to $15.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.8 million (up 32.78% YoY) and the FY2025 annual result came in at $20.8 million, up 44.54% from the prior year.
• Total Non-Current Liabilities slipped to $15.8 million in Q1 2026, from $20.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $20.8 million in Q4 2025 to a low of $4.7 million in Q3 2023.
• A 5-year average of $11.6 million and a median of $11.9 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities tumbled 34.41% — and 2024, when it soared 207.48%.
• Tracing ELDN's Total Non-Current Liabilities over 5 years: stood at $8.6 million in 2022, then plunged by 34.41% to $5.6 million in 2023, then jumped by 155.0% to $14.4 million in 2024, then surged by 44.54% to $20.8 million in 2025, then retreated by 23.94% to $15.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $15.8 million (Q1 2026), $20.8 million (Q4 2025), and $16.9 million (Q3 2025), per Business Quant data.